These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15633336)

  • 1. [Drug committees welcome the SBU hypertension report. A number of patients can be offered cost-effective, evidence-based therapy].
    Ohlsson O
    Lakartidningen; 2004 Dec; 101(49):3984-5. PubMed ID: 15633336
    [No Abstract]   [Full Text] [Related]  

  • 2. Considerations in the treatment of mild-to-moderate hypertension.
    Giaquinta D
    Manag Care Interface; 2001 Mar; 14(3):80-1. PubMed ID: 11301960
    [No Abstract]   [Full Text] [Related]  

  • 3. [The double messages about atenolol must be an issue for the SBU board].
    Werkö L; Enkvist C
    Lakartidningen; 2004 Dec; 101(49):4038, 4041; discussion 4041-2, 4045. PubMed ID: 15633347
    [No Abstract]   [Full Text] [Related]  

  • 4. Out-of-pocket costs to users: medicine options for hypertension.
    Arredondo A
    Am J Hypertens; 2008 May; 21(5):492. PubMed ID: 18437138
    [No Abstract]   [Full Text] [Related]  

  • 5. [Selection criteria in the treatment of arterial hypertension and recommended guidelines].
    Agabiti-Rosei E; Muiesan ML; Bettoni G
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 2):527-32. PubMed ID: 12497777
    [No Abstract]   [Full Text] [Related]  

  • 6. Discrepancies between use of antihypertensive drugs and guidelines indications: pharmacoeconomic implications.
    Robbiano L; Martelli A; Brambilla G
    J Hum Hypertens; 2005 Oct; 19(10):819-22. PubMed ID: 15951739
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Medical economics of hypertension therapy].
    Yamazaki T
    Nihon Rinsho; 2008 Aug; 66(8):1601-4. PubMed ID: 18700564
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comment on IOWiG report plan. A medical decision may not be replaced].
    Vorstand der Deutschen Hochdruckliga E.V
    MMW Fortschr Med; 2006 May; 148(19):42. PubMed ID: 16736705
    [No Abstract]   [Full Text] [Related]  

  • 10. An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece.
    Stafilas PC; Sarafidis PA; Lasaridis AN; Aletras VH; Niakas DA
    Am J Hypertens; 2005 Sep; 18(9 Pt 1):1233-40; discussion 1241-2. PubMed ID: 16182115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension].
    Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L
    Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623
    [No Abstract]   [Full Text] [Related]  

  • 12. [Fully possible to reduce the costs of hypertension treatment].
    Wettermark B; Angman A; Hjemdahl P
    Lakartidningen; 2009 Jun 3-9; 106(23):1558-62. PubMed ID: 19583013
    [No Abstract]   [Full Text] [Related]  

  • 13. Beta-blockers and the treatment of hypertension.
    Williams B
    J Hypertens; 2007 Jul; 25(7):1351-3. PubMed ID: 17563554
    [No Abstract]   [Full Text] [Related]  

  • 14. [The pharmaco-economics of the treatment of arterial hypertension: data and controversies].
    Rorive G; Delporte JP
    Bull Mem Acad R Med Belg; 1998; 153(7-9):317-21; discussion 322-4. PubMed ID: 10100395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
    Linjer E; Hedner T; Jönsson B; Ekbom T; Lindholm LH; Dahlöf B; de Faire U; Scherstén B;
    Blood Press; 2005; 14(2):107-13. PubMed ID: 16036488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economic issues and the future treatment and management of hypertension.
    Giles TD
    AAPPO J; 1994; 4(4):27-8, 30, 33-5. PubMed ID: 10150589
    [No Abstract]   [Full Text] [Related]  

  • 17. [Investigation and treatment of primary hypertension].
    Lindstedt I; Nilsson PM
    Lakartidningen; 2008 Jul 23-Aug 5; 105(30-31):2107-12. PubMed ID: 18751450
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmacotherapy of hypertension. How much can safely be saved?].
    Anlauf M
    MMW Fortschr Med; 2004 Apr; 146(15):57-8. PubMed ID: 15373022
    [No Abstract]   [Full Text] [Related]  

  • 19. The economic value of individualizing drug therapy.
    Navarro RP
    Manag Care Interface; 1997 Oct; 10(10):96-8. PubMed ID: 10174423
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hypertension therapy--never without diuretics?].
    Anlauf M
    MMW Fortschr Med; 2007 Nov; 149(46):31-3. PubMed ID: 18069189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.